Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19007877 | 0.90 | TSHR (0.34) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL19796651 | 0.88 | FPR2 (0.36) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL21115550 | 0.88 | TSHR (0.36) | DGAT1SOAT1CYP2C9TSHRSPHK1 | |
| SCHEMBL19007871 | 0.87 | CA1 (0.35) | DGAT1SOAT1CYP2C9TSHRSPHK1 | |
| SCHEMBL19796585 | 0.87 | CNR2 (0.36) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL19804646 | 0.86 | FFAR4 (0.35) | CYP2C9ALDH1A1MAPTCA1CA2 | |
| SCHEMBL19796638 | 0.86 | TSHR (0.36) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL19796609 | 0.86 | CNR2 (0.38) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL19007881 | 0.86 | CNR2 (0.35) | DGAT1SOAT1CYP2C9TSHRRAB9A | |
| SCHEMBL19797014 | 0.86 | RARA (0.34) | DGAT1SOAT1CYP2C9TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | DGAT1 2685/4885SOAT1 1216/4885CYP2C9 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.